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Extracellular vesicles released by hepatocytes during lip-
otoxicity carry and shuttle specific microRNA-targeting
peroxisome proliferator-activated receptor-g into hepatic
stellate cells and induce a phenotypical switch from quies-
cent to activated cells.
BACKGROUND & AIMS: Hepatic stellate cells (HSCs) play a key
role in liver fibrosis in various chronic liver disorders including
nonalcoholic fatty liver disease (NAFLD). The development of
liver fibrosis requires a phenotypic switch from quiescent to
activated HSCs. The trigger for HSC activation in NAFLD remain
poorly understood. We investigated the role and molecular
mechanism of extracellular vesicles (EVs) released by hepato-
cytes during lipotoxicity in modulation of HSC phenotype.
METHODS: EVs were isolated from fat-laden hepatocytes by
differential centrifugation and incubated with HSCs. EV inter-
nalization and HSC activation, migration, and proliferation were
assessed. Loss- and gain-of-function studies were performed to
explore the potential role of peroxisome proliferator-activated
receptor-g (PPAR-g)-targeting microRNAs (miRNAs) carried
by EVs into HSC.
RESULTS: Hepatocyte-derived EVs released during lipotoxicity
are efficiently internalized by HSCs resulting in their activation,
as shown by marked up-regulation of profibrogenic genes
(collagen-I, a-smooth muscle actin, and tissue inhibitor of
metalloproteinases-2), proliferation, chemotaxis, and wound-
healing responses. These changes were associated with miR-
NAs shuttled by EVs and suppression of PPAR-g expression in
HSCs. The hepatocyte-derived EV miRNA content included
various miRNAs that are known inhibitors of PPAR-g expres-
sion, with miR-128-3p being the most efficiently transferred.
Furthermore, loss- and gain-of-function studies identified
miR-128-3p as a central modulator of the effects of EVs on
PPAR-g inhibition and HSC activation.
CONCLUSIONS: Our findings demonstrate a link between fat-
laden hepatocyte-derived EVs and liver fibrosis and have poten-
tial implications for thedevelopmentofnovel antifibrotic targets for
NAFLD and other fibrotic diseases. (Cell Mol Gastroenterol Hepatol
2015;1:646–663; http://dx.doi.org/10.1016/j.jcmgh.2015.07.007)Keywords: Extracellular Vesicles; Hepatic Stellate Cell; Lip-
otoxicity; Liver Fibrosis; miRNAs.
onalcoholic fatty liver disease (NAFLD) hasNemerged as a serious public health problem in the
United States and many other countries.1,2 It affects both
adults and children and may progress to cirrhosis and end-
stage liver disease.3–6 An increased fat deposit in the liver is
an early event and a prerequisite for the development of
NAFLD.7,8 Considerable evidence supports the concept that
certain lipids, such as saturated free fatty acids (FFAs),
contribute to disease progression through toxic effects on
hepatocytes. Indeed, lipotoxicity may result in hepatocyte
damage, triggering an inflammatory reaction and abnormal
wound-healing response that results in the development of
nonalcoholic steatohepatitis (NASH) and fibrosis.6,9,10 Pa-
tients with fibrotic NASH are at significant risk for disease
progression to cirrhosis with significant increase in liver-
related morbidity and mortality.8,11,12
Hepatic stellate cells (HSCs) play a crucial role during
liver fibrosis in various chronic liver disorders, including
NAFLD.13 During liver fibrogenesis, HSCs undergo a
phenotypical switch from quiescent vitamin A–storing cells
to activated and proliferative myofibroblast-like cells in a
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various genes, including a-smooth muscle actin (a-SMA),
collagen-1a1, tissue inhibitor of metalloproteinases (TIMP-1
and 2), and transforming growth factor-b (TGF-b).14 Acti-
vated HSCs play a crucial role in sustaining and promoting
extracellularmatrix deposition, and they acquire the ability to
proliferate and migrate toward the area of injury.13,15
Currently, the molecular mechanisms linking fat-laden he-
patocytes to HSC activation remain incompletely understood.
We have recently demonstrated that extracellular vesi-
cles (EVs) membrane-bound vesicles released during cell
stress or death that are key cell-to-cell communicators are
released both in vitro in cultured hepatocytes exposed to
saturated free fatty acids and in vivo in animal models of
NASH.16,17 In these studies, the levels of circulating EVs
strongly correlated with the severity of liver fibrosis, and
treatment with a neutralizing antibody for Vanin-1 (VNN1) a
surface protein identified in proteomic analysis of EVs
played a crucial role in modulating the internalization of EVs
into target cells. Based on this evidence, we tested the hy-
pothesis that EVs released by hepatocytes during lip-
otoxicity carry and transfer microRNAs (miRNA, miR) that
regulate fibrogenesis by inducing a phenotypical switch
from quiescent to activated HSCs.Materials and Methods
Animal Studies
Male C57BL/6 wild-type (WT) mice, 20 to 25 g of body
weight, 7 weeks old, were placed on a choline-deficient L-
amino acid (CDAA) diet or control diet of choline supple-
mented L-amino acid (CSAA) (n ¼ 12) (Dyets, Bethlehem,
PA) for 20 weeks to induce NASH.18 In addition, six mice
were placed on a high-fat diet (45% kcal from fat, 18.8 kJ/g)
(Research Diets, New Brunswick, NJ) or normal chow for 12
weeks as an alternative model of diet-induced NAFLD.19 The
mice were sacrificed, and the liver and blood were collected
under anesthesia achieved by injecting intraperitoneally,
with a 21G needle, a mixture of 100 mg/kg of ketamine and
10 mg/kg of xylazine dissolved in a 0.9% saline solution.20
The studies were approved by the University of Califor-
nia San Diego Institutional Animal Care and Use Committee
and followed the National Institutes of Health guidelines
outlined in “Guide for the Care and Use of LaboratoryFigure 1. (See previous page). Hepatocyte-derived extracellu
(HSC) and induce up-regulation of profibrogenic markers
(HepG2-EVs) and primary mouse hepatocyte EVs (PMH-EVs) l
cells (LX2) and primary mouse hepatic stellate cells (mHSC) as
cubation with EVs and imaged by confocal microscope using 40
was used to block EV internalization. (B) Quantitative polymera
muscle actin (a-SMA), collagen type 1, and tissue inhibitor of me
hours with or without a Vanin-1 neutralizing antibody. (C) Wester
actin (a-SMA), TGF-b (transforming growth factor-b), (connective
GFAP in LX2 exposed to Hep-EVs for 24 hours with or without VN
normalized to actin. (E) Quantitative qRT-PCR analyses for profi
hepatic stellate cells (mHSC) to PMH-EVs for 16 hours with o
housekeeping gene for qRT-PCR, and actin and tubulin were us
mean ± SD from three independent experiments. *P < .05, **P <
Whitney test and Bonferroni correction.Animals.” Collection of liver specimens, H&E staining, and
NAFLD activity score analysis were performed as previously
described elsewhere.17
Cell Culture
Human hepatoma cell line (HepG2) was maintained in
Dulbecco’s modified Eagle’s medium (DMEM; Life Technol-
ogies, Grand Island, NY), supplemented with 10% fetal
bovine serum (FBS; CellGro, Manassas, VA), 5000 U/mL
penicillin, and 5000 mg/mL streptomycin sulfate in 0.85%
NaCl and 5% sodium pyruvate (Sigma-Aldrich, St. Louis,
MO). Long-chain FFAs, palmitic acid (Sigma-Aldrich) was
dissolved in 95% ethanol (stock solution 100 mM) and
stored at 20 C before the experiments. Human immor-
talized hepatic stellate cells (LX2) were kindly provided by
Prof. Scott Friedman; they were cultured in DMEM, sup-
plemented with 1% FBS (CellGro) and 5000 U/mL penicillin
and 5000 mg/mL streptomycin sulfate in 0.85% NaCl.
Hepatocyte Isolation
Primary murine hepatocytes were isolated by using a two-
step method previously described elsewhere.21 Briefly, WT
C57/B6 mice were deeply anesthetized, the abdominal cavity
was opened and livers were perfused in situ with EGTA for
5 minutes and collagenase D (Roche Diagnostics, Indian-
apolis, IN) for 10 minutes at a flow rate of 10 mL/min. After
perfusion, the partially digested liver was excised, and the
digest was passed through a 70-mm nylon mesh to remove
undigested materials. Purified hepatocytes were seeded on
collagen-coated culture dishes and cultured in William’s
E media (Life Technologies) supplemented with 10% FBS
and 5000 U/mL penicillin and 5000 mg/mL streptomycin
sulfate in 0.85% NaCl. Hepatocyte vitality was determined
by Tripan blue staining and counting on a hemacytometer.
Experiments were performed the day after the isolation.
Hepatic Stellate Cell Isolation
Primary mouse hepatic stellate cells (mHSCs) were iso-
lated from WT C57/B6 mice by previously published pro-
tocols.21,22 Briefly, livers were perfused in situ with EGTA
for 5 minutes, with pronase E (0.4 mg/mL, Roche Di-
agnostics) for 5 minutes, and collagenase D (0.5 mg/mL;
Roche Diagnostics) for 8 minutes at a flow rate of 5 mL/min.lar vesicles (EVs) are internalized into hepatic stellate cells
. (A) Internalization of HepG2-derived extracellular vesicles
abeled with PKH26 into immortalized human hepatic stellate
sessed by indirect immunofluorescence after 6 hours of in-
 magnification. A Vanin-1 neutralizing antibody (VNN1 nAb)
se chain reaction analyses for profibrogenic genes a-smooth
talloproteinases-2 (TIMP-2) in LX2 exposed to Hep-EVs for 16
n blot analysis of markers of HSC activation a-smooth muscle
tissue growth factor) CTGF, and (glial fibrillary acidic protein)
N1 nAb. (D) Quantification of a-SMA and CTGF protein levels
brogenic genes a-SMA and collagen type 1 in primary mouse
r without VNN1 nAb. b2-Microglobulin (B2M) was used as
ed as loading controls for Western blotting. Values represent
.005, ***P < .0005, Kruskal-Wallis test with post–hoc Mann-
Figure 2. Hepatocyte-derived extracellular vesicles (EVs) induce migration, wound-healing response, and proliferation
of hepatic stellate cells. (A) Representative microphotographs (10 magnification) and (B) corresponding quantification
histogram of Boyden’s chamber assay of human immortalized hepatic stellate cells (LX2) exposed to HepG2-derived EVs
(Hep-EV) for 16 hours. (C) Representative microphotographs and (D) corresponding quantification graph of wound-healing
assay of LX2 treated with Hep-EVs for 24 hours. (E) Quantification graph of proliferation assay of LX2 treated with Hep-EVs
for 48 hours. A Vanin-1 neutralizing antibody was used to block the internalization of Hep-EVs. Values represent mean ±
standard deviation from three independent experiments. *P < .05, **P < .005, ***P < .0005, Kruskal-Wallis test with post hoc
Mann-Whitney test and Bonferroni correction.
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fully digested in collagenase D, pronase E, and DNAse I
(2 mg/mL, Roche Diagnostics) for 15 minutes. The digested
livers were filtered through a cell strainer and washed with
Gey’s balanced salt solution. HSCs were purified from other
parenchymal and nonparenchymal liver cells by flotation on
6.4% (w/v) Nicodenz (Axis-Shield PoC AS, Oslo, Norway)/
Gey’s balanced salt solution (without NaCl).
The purity of the HSCs was assessed by detecting
vitamin A autofluorescence. The cells were counted, and
approximately 0.2  106 cells were seeded onto a 12-well
plate in high-glucose DMEM media containing 10% FBS,
1% penicillin/streptomycin, and 1% HEPES (Sigma-Aldrich)
for up to 7 days. Cells were imaged every day with an
Olympus contrast phase microscope (Olympus America,
Center Valley, PA), and they were treated with primary
hepatocyte-derived microparticles on day 2 from isolation
and for 48 hours before performing the experiments.Extracellular Vesicle Isolation
HepG2 and primary mouse hepatocytes (PMH) were
seeded onto a 100-mm dish or six-well plate, respectively,
and cultured until reaching 80% to 85% confluence. Cells
were incubated with 0.25 mM palmitic acid in serum-free
DMEM supplemented with 1.1% penicillin and strepto-
mycin, and 1% endotoxin-free bovine serum albumin for up
to 24 hours. Extracellular vesicles were isolated by differ-
ential centrifugation, as previously described elsewhere.16
Briefly, collected medium was centrifuged twice at
1700g for 15 minutes to remove cell debris and aggregates.
The supernatant was then transferred to new tubes and
ultracentrifuged at 100,000g for 90 minutes at 10C.23 The
supernatant was collected in new tubes and used as the EV-
free control, and the pelleted EVs (13–15  103/mL me-
dium/100-mm petri dish) were resuspended in 500 mL of
serum-free DMEM for subsequent in vitro studies.
To trace the hepatocyte-derived EVs (Hep-EV), PKH26
dye (Sigma-Aldrich) was used according to the manufac-
turer’s instructions. A complete characterization of Hep-EVs,
including size, composition, and distribution, was performed
by dynamic light scattering, transmission electron micro-
scope, liquid chromatography with tandem mass spec-
trometry, and fluorescence-activated cell sorting as reportedFigure 3. (See previous page). Hepatocyte-derived extracellu
activated receptor-g (PPAR-g) by shuttling specific micro
analysis of PPAR-g in human immortalized hepatic stellate cells
with or without Vanin-1 neutralizing antibody (VNN1 nAb). (B) We
Hep-EVs for 24 hours in the presence or absence of VNN1 nAb
hepatic stellate cells (mHSCs) treated with primary mouse hep
VNN1 nAb. b2-Microglobulin (B2M) was used as housekeepin
control for Western blotting. (D) Representative confocal microp
positive Hep-EVs (red) and EV-RNA content labeled with SY
miR-128-3p, miR-27b, and miR-130b in LX2 treated with Hep-EV
analysis of miR-128-3p in EVs isolated from HepG2 treated
Quantitative PCR of PPAR-g-targeting miR-128-3p in (mHSC) tre
Quantitative PCR analysis of miR-128-3p in EVs isolated from P
hours. U6 was used as the control. Values represent mean ± sta
**P < .005, ***P < .0005, Kruskal-Wallis test with post hoc Manpreviously elsewhere.16 In selected studies, Hep-EV were
incubated with 10 mg/mL of RNase (Roche Diagnostics) for
30 minutes at 37C to remove any RNA adhering to the
external leaflet.Cell Transfection
Transfection of miR-128-3p MISSION microRNA MIMIC
(Sigma-Aldrich) and mirVana miR-128-3p inhibitor in LX2
was obtained by using Lipofectamin RNAiMAX transfection
reagent (Life Technologies). Briefly, LX2 cells were plated at
a density of 0.5–4  105 cell/well in a 12-well or 24-well
plate and transfected with 75 nM of miR-128-MIMIC or 30
nM of AntagomiR-128-3p. Transfected cells were incubated
at 37C with serum-free and antibiotic-free Opti-MEM for
6 hours, then the medium was replaced with standard cul-
ture medium supplemented with 1% FBS. After 24 hours
the cells were treated with hepatocyte-derived EVs or con-
trols for an additional 48 hours and then harvested or used
for subsequent experiments. Anti-miR Negative Control
(Life Technologies) and miRIDIAN microRNA Mimic Nega-
tive Control (Sigma-Aldrich) were used as the negative
controls.
For HepG2 transfection with Dicer1 and Drosha silencing
RNA (siRNA) mixture, we used Lipofectamine 2000 (Life
Technologies) according to the manufacturer’s instructions.
Briefly, HepG2 (3  105 cell/well in a six-well plate) were
transfected with 40 nM of Silencer Select Dicer1 and Drosha
siRNA (IDs: s23756 and s26492; Life Technologies) in Opti-
MEM and incubated at 37C for up to 6 hours. After 6 hours
Opti-MEM was replaced with regular medium with 10%
FBS. After 48 hours from transfection, the cells were treated
with or without 0.25 mM of palmitic acid (Sigma-Aldrich) or
vehicle (1% endotoxin-free, low-FFA bovine serum albu-
min) for 24 hours. After the incubation with palmitic acid,
the EVs were isolated, and the cells were harvested for
protein and RNA isolation.
Silencing efficacy was assessed by quantitative poly-
merase chain reaction (qPCR) and Western blot analyses.
Transfection of mirVana miR-128-3p inhibitor in HepG2 was
obtained using Lipofectamine RNAiMAX transfection re-
agent (Life Technologies) according to the manufacturer’s
instructions. Briefly, HepG2 were seeded at a density of
0.5–1  106 in a six-well plate and transfected with 30 nMlar vesicles (EVs) down-regulate peroxisome proliferator-
RNAs. (A) Quantitative polymerase chain reaction (qPCR)
(LX2) treated with HepG2-derived EVs (Hep-EVs) for 16 hours
stern blot analysis of PPAR-g protein level in LX2 treated with
. (C) Quantitative PCR analysis of PPAR-g in primary mouse
atocyte-derived EVs (PMH-EVs) for 16 hours with or without
g gene for quantitative PCR, and actin was used as loading
hotographs of internalization (60 magnification) of PKH26-
TO RNA (green). (E) Quantitative PCR of PPAR-g-targeting
s for 16 hours with or without VNN1 nAb. (F) Quantitative PCR
with 0.25 mM of palmitic acid or vehicle for 24 hours. (G)
ated with Hep-EVs for 16 hours with or without VNN1 nAb. (H)
MH-EVs treated with 0.25 mM of palmitic acid or vehicle for 24
ndard deviation from three independent experiments. *P <.05,
n-Whitney test and Bonferroni correction.
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37C with serum-free and antibiotic-free Opti-MEM for 6
hours and then the medium was replaced with serum-free
DMEM with 0.25 mM of palmitic acid and 1% low-
endotoxin FFA-free bovine serum albumin for 24 hours. Af-
ter 24 hours of incubation, the EVs were isolated. Isolation of
RNA and miRNAs was performed as described herein.Migration Assays
In vitro migration studies have been performed by using
LX2 cells and primary mouse HSCs. The wound-healing
assay was performed to analyze HSC nonoriented migra-
tion (chemokinesis) by using Radius 24-well Cell Migration
Assay (Cell Biolabs, San Diego, CA) according to the manu-
facturer’ instructions. The HSC were seeded onto the radius
November 2015 Extracellular Vesicles and Liver Fibrosis 653of a 24-well plate and treated with Hep-EV or controls for
24 hours. Analysis of the number of migrated cells onto the
radius was performed and quantification reported in his-
togram. Mitomycin (1 mg/mL) was used to inhibit cell pro-
liferation during the wound-healing assay. Boyden’s
chamber assay was performed to analyze the HSC-oriented
migration (chemotaxis) by using cell culture inserts of 8-mm
pore size (Millipore, Billerica, MA) and a 24-well plate. Each
well was filled with 500 mL of serum-free DMEM with Hep-
EVs or controls.
For some selected studies, HSCswere incubatedwithHep-
EVs with anti-Vanin-1 neutralizing antibody, miR-128-3p
mimic, anti-miR-128-3p, or Hep-EVs isolated from HepG2
transfected with Dicer/Drosha siRNA. The inserts were
placed on top of each well, and 150 mL of cell suspension (5
104 cells) was added. The plates were incubated overnight at
37C, and then the filters were removed and stained with
Vectashield mounting medium with 40,6-diamino-2-
phenylindole (DAPI) (Vector Laboratories, Burlingame, CA).
Migrated cells were detectedwith a fluorescencemicroscope,
and the number per field of their nuclei was counted.
Proliferation Assay
The HSC proliferation assay was performed by detecting
DNA synthesis via incorporation of 5-bromo-2-deoxyuridine
(BrdU) using a CyQuant Direct Cell Proliferation Assay (Life
Technologies) according to the manufacturer’ instructions.
The HSCs were plated onto a 96-well plate (0.15  105 cell/
well) and treated with controls or testing compounds for
48 hours. A bottom-read plate reader was used to detect
fluorescein isothiocyanate-positive signals. The relative
fluorescence was reported in the quantification graphs as
the fold-change to the control.
Western Blot Analysis
The HSCs were digested in 400 mL of radio-
immunoprecipitationassaybuffer containingPhosphatase and
Protease Inhibitor Cocktail (Roche Diagnostics). After cellular
lysis, 30–50 mg of protein was solubilized in Laemmli buffer,
resolved by a 4%–20% Criterion Tris-HCl gel electrophoresis
system (Bio-Rad Laboratories, Hercules, CA) and transferred
to a 0.2-mm nitrocellulose membrane (Bio-Rad Laboratories).
Primary rabbit polyclonal ormousemonoclonal antibody anti-
human TGF-b (Cell Signaling Technology, Beverly, MA), a-
SMA, peroxisome proliferator-activated receptor-g (PPAR-g),Figure 4. (See previous page). An artificial exposure of hepat
profibrogenic responses induced by miR-128-3p shuttled
Graphical summary of gain-of-function approach in HSCs. (B
peroxisome proliferator-activated receptor-g (PPAR-g) in human
EVs, miR-128-3p mimic or negative control mimic for 16 hours. (C
with HepG2-EVs, miR-128-3p mimic, or negative control mimic
genes a-smooth muscle actin (a-SMA) and collagen type 1 in
control mimic for 16 hours. b2-Microglobulin (B2M) was used as
control for Western blotting. (E) Proliferation assay of 5-bromo
miR-128-3p mimic or negative control mimic for 48 hours. (F
quantification graph of Boyden’s chamber assay of LX2 incubat
mimic for 16 hours. Values represent mean ± standard deviatio
***P < .0005, Kruskal-Wallis test with post hoc Mann-WhitneyDicer1, tubulin, connective tissue growth factor (CTGF), glial
fibrillary acidic protein (GFAP) (1:1000; Genetex, Irvine, CA),
and actin (1:5000; Genetex) were incubated overnight at 4C.
Primary antibodies were detected by using appropriate
horseradish peroxidase–secondary antibodies (Cell Signaling
Technology). Proteins were visualized by Supersignal West
Pico chemiluminescence reagents (Pierce Biotechnology,
Rockford, IL). Western blot data were obtained from three
independent experiments, and a representative gel is shown in
the figures.
RNA Isolation and Quantitative Real-Time
Polymerase Chain Reaction
Total RNAwas isolatedusingRNeasy kit (Qiagen, Valencia,
CA) and reverse transcribed by iScript cDNA synthesis kit
(Bio-Rad Laboratories) according to the manufacturer’s in-
structions. Quantitative real-time PCR (qRT-PCR) was per-
formed on a BioRad Cycler (Bio-Rad Laboratories) by use of
SYBRGreen real-time PCR master mix (Kapabiosystem,
Woburn, MA) according to the manufacturer’s instructions.
The housekeeping gene b2-microglobulin (B2M) was used as
the internal control. The PCR primers used to amplify each
gene are listed in Supplementary Table 1.
MiRNAs were isolated from hepatocytes, Hep-EVs, HSCs,
or murine liver tissue by miRNeasy Mini kit (Qiagen), and
miRNA expression was analyzed by using the TaqMan
microRNA Reverse Transcription kit and TaqMan Universal
PCR kit (Life Technologies) on 7300 Real-time PCR system
(Life Technologies). Identification of miRNAs targeting
PPAR-g was assessed by combining computational data
from three prediction algorithms: miRanda, TargetScan, and
mirWalk. We selected three of the most conserved miRNAs:
miR-130b, miR-128-3p, and miR-27b. Specific primers for
selected miRNAs (Life Technologies) were used in separate
reactions, and the fold-change expression with respect to
control was calculated for all samples. The U6 small-nuclear
RNA was used as a control (Life Technologies).
Incorporation of EVs in Hepatic Stellate Cells and
Transfer of RNA
Incorporation of Hep-EVs into HSCs was evaluated
by confocal microscope after the incubation of 0.15  105
HSC/well with PKH26-positive EVs for up to 6 hours in a
four-well tissue culture slide. In selected studies, Hep-EVs
were incubated overnight at 4C with Vanin-1 (Genetex)ic stellate cells (HSC) to miR-128-3p mimic showed similar
by HepG2-derived extracellular vesicles (Hep-EVs). (A)
) Quantitative polymerase chain reaction (qPCR) analysis of
immortalized hepatic stellate cells (LX2) treated with HepG2-
) Western blot analysis of PPAR-g protein level in LX2 treated
for 24 hours. (D) Quantitative PCR analyses for profibrogenic
LX2 treated with HepG2-EVs, miR-128-3p mimic or negative
housekeeping gene for qPCR, and actin was used as loading
-2-deoxyuridine–positive LX2 after exposure to HepG2-EVs,
) Representative microphotographs and (G) corresponding
ed with HepG2-EVs, miR-128-3p mimic, and negative control
n from three independent experiments. *P < .05, **P < .005,
test and Bonferroni correction.
Figure 5. Loss of function of miR-128-3p in hepatic stellate cells (HSC) rescued PPAR-g expression and reduced
activation, migration and proliferation. (A) Graphical summary of loss-of-function approach in hepatic stellate cells (HSCs).
(B) Quantitative polymerase chain reaction (qPCR) analysis of peroxisome proliferator-activated receptor-g (PPAR-g) in human
immortalized hepatic stellate cells (LX2) treated with HepG2-derived extracellular vesicles (Hep-EVs), AntagomiR-128-3p, or
anticontrol for 16 hours. (C) Western blot analysis of PPAR-g protein level in LX2 treated with Hep-EVs, antagomiR-128-3p, or
anticontrol for 24 hours. (D) Quantitative polymerase chain reaction (qPCR) analyses for profibrogenic genes a-smooth muscle
actin (a-SMA) and collagen type 1 in LX2 treated with Hep-EVs, antagomiR-128-3p or anticontrol for 16 hours. b2-
Microglobulin (B2M) was used as housekeeping gene for quantitative PCR, and actin was used as loading control for
Western blotting. (E) Proliferation assay of 5-bromo-2-deoxyuridine–positive LX2 after exposure to Hep-EVs, AntagomiR-128-
3p or anticontrol for 48 hours. (F) Representative microphotographs and (G) corresponding quantification graph of Boyden’s
chamber assay of LX2 incubated with Hep-EVs, AntagomiR-128-3p or anticontrol for 16 hours. Values represent mean ± SD
from three independent experiments. *P < .05, **P < .005, ***P < .0005, Kruskal-Wallis test with post hoc Mann-Whitney test
and Bonferroni correction.
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of EVs into HSCs. To analyze the RNA transfer into HSCs by
Hep-EVs, we incubated Hep-EVs with RNA fluorescein
isothiocyanate-positive stain SYTO RNASelect (Life Technolo-
gies) and then with PKH26 (Sigma-Aldrich) to label the EV
membrane, according to themanufacturer’s instructions. HSCs
were incubated with PKH26/SYTO-positive EVs for up to 6
hours, and the fluorescence intensity was evaluated by
Olympus FV1000 Spectral Confocal microscope. The miRNA
transfer to HSCs was also evaluated by qRT-PCR at different
timepoints (3hours, 6 hours, 16hours, and24hours).Weused
40,6-diamidino-2-phenylindole stain (DAPI) to label cell nuclei.
A 40 magnification was used for the microphotographs.Statistical Analysis
All data are expressed as mean ± standard deviation (SD)
unless otherwise indicated. Differences between three or
more groups were compared by a nonparametric Kruskal-
Wallis analysis of variance (ANOVA) test. If a statistically
significant effectwasdetected, post hocpairwise comparisons
were performed using Mann-Whitney tests with Bonferroni
correction. Differences between two groups were compared
with a two-sided Student t test if the data were normal or a
Mann-Whitney test if the data deviated from the normal dis-
tribution. P < .05 was considered statistically significant. All
statistical analyses were performed using GraphPad Prism
4.0c (La Jolla, CA) or R v3.0.2 (www.r-project.org).
Results
Hepatocyte-Derived Extracellular Vesicles
Released During Lipotoxicity Are Internalized Into
Hepatic Stellate Cells and Induce Their Activation
We have recently demonstrated that while cultured he-
patocytes released a small number of EVs into the superna-
tant, treatment of these cells with lipotoxic fatty acids results
in a several-fold increase in the number of EVs released.16 The
EVs released by lipotoxic hepatocytes (Hep-EV) are enriched
in VNN1 protein.16 To study the effects of Hep-EVs on HSCs,
we initially assessed whether Hep-EVs released by HepG2
(hepatoma cells) or PMH exposed to palmitic acid for 24
hourswere internalized intoHSCs. To address this, HSCswere
exposed to Hep-EVs labeled with PKH26 (a lipophilic dye
binding the cell membrane) for 1, 3, or 6 hours. We observedFigure 6. (See previous page). Depletion of the microRNA ma
vesicles (Hep-EVs) with reduced profibrogenic effect on HS
in HepG2 to generate miRNA-reduced EVs released during lip
Drosha (Dro) in HepG2 treated with Dcr/Dro silencing RNA (siRN
mM of palmitic acid or vehicle for 24 hours for EV release. (C) W
silencing RNA (siRNA) and scramble RNA (scRNA) for 72 hou
for quantitative polymerase chain reaction (PCR), and actin
(D) Quantitative PCR analysis of miR-128-3p amount in Hep-EV
(E) Proliferation assay of 5-bromo-2-deoxyuridine–positive LX2
scRNA-treated HepG2 and Dcr/Dro siRNA-treated HepG2 (Dcr
microphotographs and (G) corresponding quantification histogra
from palmitic acid-treated HepG2, scRNA-treated HepG2 and D
acid exposure. Values represent mean ± standard deviation
***P < .0005, Kruskal-Wallis test with post hoc Mann-Whitneythat Hep-EVs (HepG2-EVs and primary mouse hepatocyte-
EVs) were internalized into both human immortalized HSCs
(LX2) and primary mouse HSCs (primary mHSC) particularly
after 6 hours of incubation (Figure 1A). To assesswhether the
internalization was dependent on Vanin-1 (VNN1), as previ-
ously demonstrated,16 we preincubated Hep-EVs with 4 mg/
mL of VNN1 neutralizing antibody (VNN1 nAb). We observed
that theHep-EV uptakewas dramatically reduced (Figure 1A)
by blocking VNN1 on the EV external leaflet. Treatment of
Hep-EVs with a blocking antibody against GAPDH had no ef-
fect on Hep-EV internalization into both human and mouse
HSCs, suggesting a key role of VNN1 inHep-EV internalization
into HSCs (Supplementary Figure 1).
To analyze the effect of internalized Hep-EVs on the
modulation of HSC phenotype, we exposed human (LX2) and
mouse primary HSCs to Hep-EVs for up to 16 hours. Subse-
quently, we analyzed mRNA expression for various markers
of HSC activation, including a-smooth muscle actin (a-SMA),
collagen-1a1, and tissue inhibitor growth factor-2 (TIMP-2)
by qRT-PCR. LX2 cells incubated with Hep-EVs showed a
significant up-regulation of a-SMA, collagen-1a1, and TIMP-2
compared with untreated LX2 (control) and LX2 treated with
EV-free supernatant (Figure 1B). These results matched with
increased protein levels of a-SMA, TGF-b, CTGF, and GFAP,
markers of HSC activation (Figure 1C and D).13
To confirm these findings in primary cells, we exposed
primary mouse HSCs (primary mHSC) to primary
hepatocyte-derived EVs (PMH-EV) released during lip-
otoxicity. Similar to the findings observed for LX2, a-SMA
and collagen-1a1 were both markedly up-regulated in pri-
mary mHSC by the exposure to EVs compared with controls
(Figure 1E). Notably, internalization of Hep-EVs and up-
regulation of HSC activation were dramatically reduced by
blocking Vanin-1 with VNN1 nAb (Figure 1A–E).
Extracellular Vesicles Released by Lipotoxic
Hepatocytes Induce Hepatic Stellate Cell
Migration and Proliferation
During hepatic fibrosis, the activation, migration, and
proliferation of HSCs occur rapidly in response to various
stimuli present in the extracellular environment and
released during liver injury. To investigate Hep-EVs released
during lipotoxicity-induced HSC profibrogenic responses,
we exposed LX2 to Hep-EVs and tested oriented migrationchinery in HepG2 resulted in HepG2-derived extracellular
C. (A) Graphical summary of double-silencing of Dicer/Drosha
otoxicity. (B) Quantitative PCR analysis of Dicer1 (Dcr) and
A) or scramble RNA (scRNA) for 48 hours and exposed to 0.25
estern blot analysis of Dicer in HepG2 treated with or without
rs. b2-Microglobulin (B2M) was used as housekeeping gene
was used as loading control for Western blot analysis.
s released from HepG2 treated with Dcr/Dro siRNA or scRNA.
exposed to EV isolated from palmitic acid-treated HepG2,
/Dro-) followed by palmitic acid exposure. (F) Representative
m of Boyden’s chamber assay of LX2 exposed to EVs derived
cr/Dro siRNA-treated HepG2 (Dcr/Dro-) followed by plamitic
from three independent experiments. *P < .05, **P < .005,
test and Bonferroni correction.
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proliferation. The exposure of LX2 to Hep-EVs resulted in a
marked stimulation of cell chemotaxis (Figure 2A and B),
chemokinesis (Figure 2C and D), and DNA synthesis as an
index of proliferation (Figure 2E) compared with untreatedcells or cells treated with EV-free supernatant. To further
analyze whether blocking Hep-EV internalization could
reduce HSC activation, we neutralized Vanin-1 on the Hep-
EVs surface. Notably, we observed a significant reduction
of LX2 migration (chemotaxis and chemokinesis) and
658 Povero et al Cellular and Molecular Gastroenterology and Hepatology Vol. 1, No. 6proliferation (Figure 2A–E). Taken together, these findings
demonstrate that EVs released by hepatocytes exposed to
lipotoxic palmitic acid are efficiently internalized into HSCs
in a process that, at least in part, depends on the expression
of VNN1 on the EV surface and that they induce HSC
activation.
Extracellular Vesicles Mediate the Profibrogenic
Effects of Hepatic Stellate Cells by Transferring
Specific Peroxisome Proliferator-Activated
Receptor-g-Targeting MicroRNAs
Several studies support a central role of PPAR-g as key
mediator in maintaining a quiescent HSC phenotype in
normal liver.24–26 Notably, it has been shown that PPAR-g
progressively decreases during primary HSC activation
in vitro and that it is completely depleted in fully activated
HSCs.25,27 The molecular mechanisms responsible for the
changes in PPAR-g expression during HSC activation remain
incompletely understood. To investigatewhether hepatocyte-
derived EVs induce a phenotypical switch from quiescent to
activated HSCs by regulating PPAR-g expression, we exposed
LX2 cells to Hep-EVs, and determined the mRNA and protein
expression level of PPAR-g. Exposure of LX2 to Hep-EVs,
particularly for 16hours (Supplementary Figure 3A), resulted
in a 50% reduction of PPAR-g mRNA expression compared
with untreated cells and cells treated with EV-free superna-
tant (Figure 3A). The decrease of the PPAR-gmRNA level was
concomitant with a marked reduction of the PPAR-g protein
level after 24 hours of exposure to Hep-EVs (Figure 3B). To
further confirm these findings, we exposed PMH to palmitic
acid and collected and quantified PMH-derived EVs
(Supplementary Figure 2A and B).
Primary mouse quiescent HSCs isolated from WT mice
were incubated with PMH-EVs on day 2 from isolation and
for 24 hours, when they still have a quiescent phenotype
(Supplementary Figure 2C). As previously observed for LX2
cells, PPAR-g mRNA expression resulted in a 90% down-
regulation in EV-treated primary mHSCs compared with
untreated cells (control) and mHSC treated with EV-free
supernatant (Figure 3C). In both human immortalized and
primary mouse HSCs, PPAR-g mRNA and protein levels
were unchanged or not significantly changed, compared
with controls, by blocking EVs internalization with Vanin-1
neutralizing antibody (VNN1 nAb) (Figure 3A–C).Figure 7. (See previous page). Specific depletion of miR-1
significantly reduced hepatic stellate cell (HSC) profibroge
inhibit miR-128-3p in palmitic acid-treated HepG2 and generate
reaction (qPCR) analysis of miR-128-3p expression in HepG2 tra
to 0.25 mM of palmitic acid. (C) Quantitative PCR analysis of miR
anticontrol and antagomiR-128-3p. Mean values were normalize
expression of profibrogenic genes a-SMA, TIMP-1, and collage
treated with miR-128-3p-depleted Hep-EV, Hep-EV, or Hep-EV i
(B2m) was used as housekeeping gene. (E) Proliferation assay of
128-3p-depleted Hep-EV, Hep-EV, or Hep-EV isolated from an
microphotographs and (G) corresponding quantification graph o
depleted Hep-EV, Hep-EV, or Hep-EV isolated from anticontro
standard deviation from three independent experiments. *P < .0
Mann-Whitney test and Bonferroni correction.It has been extensively reported that EVs carry and
transfer a variety of different bioactive molecules, such as
mRNA, miRNAs, proteins, and lipids16,28–31 from the cell of
origin to the target cell. Currently,miRNAs have been found to
play essential roles in HSC differentiation, proliferation,
apoptosis, and migration. Studies have shown that up-
regulation of miR-126 in HSCs promoted hepatic fibrosis by
down-regulating IkBa.32 In other studies, overexpression of
miR-150 andmiR-194 resulted in cell proliferation inhibition
in LX-2 as well as reduction in collagen type 1 and a-SMA via
inhibition of c-myb and rac1 expression.33,34 Furthermore,
previous reports have identified and validated several
microRNAs that target PPAR-g.35,36 Here, we tested whether
Hep-EVs carry some specific microRNAs targeting PPAR-g
and transfer them into HSC, enhancing their profibrogenic
activation. EVs isolated from fat-laden hepatocytes were
double-labeledwith SYTOgreenfluorescent nucleic acid stain
for EV-RNA and PKH26 for EV membrane. Confocal micro-
scopic imaging identified EVs containing RNA incorporated
into HSCs after 6 hours of exposure (Figure 3D).
We further identified the level of three validated miRNAs
targetingPPAR-g:miR-128-3p,miR-27b, andmiR-130b.35,37–39
We identified all threemiRNAs in LX2 exposed to Hep-EVs. We
observed that LX2 cells were enriched in all three miRNAs
compared with the untreated cells, but only the amount of
miR-128-3p was dramatically reduced by neutralizing Vanin-1
on EVs, suggesting that EV internalization is a key mechanism
for shuttling miR-128-3p into target cells (Figure 3E).
To confirm these results, we quantified the amount of
miR-128-3p in EVs isolated from palmitic acid-treated
HepG2, and observed that EVs were particularly enriched
in this miRNA compared with control-treated HepG2
(Figure 3F). These results were confirmed by similar results
in primary mouse HSCs incubated with palmitic acid-treated
PMH-EV (Figure 3G and H). These findings suggest that Hep-
EVs carry and shuttle PPAR-g-targeting miRNAs in HSCs,
thus promoting their activation.
In Vitro Manipulation of MicroRNA-128-3p With
Gain- and Loss-of-Function Approaches Results
in Differential Modulation of Hepatic Stellate Cell
Phenotype
To evaluate the profibrogenic role of miR-128-
3p encapsulated in Hep-EVs, we used different gain- and28-3p in HepG2-derived extracellular vesicles (Hep-EVs)
nic responses. (A) Graphical summary of approach used to
miR-128-3p-depleted EVs. (B) Quantitative polymerase chain
nsfected with antagomiR-128-3p, or anticontrol, and exposed
-128-3p level in Hep-EV released by HepG2 transfected with
d to U6 small-nuclear RNA. (D) Quantitative PCR analyses of
n1a1 as well as of the HSC quiescent marker PPAR-g in LX2
solated from anticontrol transfected HepG2. b2-Microglobulin
5-bromo-2-deoxyuridine–positive LX2 after exposure to miR-
ticontrol transfected HepG2, for 48 hours. (F) Representative
f Boyden’s chamber assay of LX2 incubated with miR-128-3p-
l transfected HepG2, for 16 hours. Values represent mean ±
5, **P < .005, ***P < .0005, Kruskal-Wallis test with post hoc
November 2015 Extracellular Vesicles and Liver Fibrosis 659loss-of-function approaches. First, we treated LX2 with miR-
128-3p mimic, which reproduces mature endogenous miR-
128-3p, or negative control mimic (Figure 4A). LX2 cells
transfected with miR-128-3p Mimic showed a significant
down-regulation of PPAR-g mRNA, as well as protein,
compared with LX2 transfected with negative control mimic,
or cells treated with EV-free supernatant (Figure 4B and C).
Additionally, miR-128-3p mimic induced a significant up-
regulation in the levels of miR-128-3p (Supplementary
Figure 3B) and profibrogenic genes a-SMA and collagen-
1a1 compared with controls (Figure 4D). We then analyzed
whether miR-128-3p mimic also modulated LX2 profibro-
genic responses. In this regard, we observed a dramatic
increase of LX2 cell mitogenic activity (Figure 4E), as well as
chemotaxis (Figure 4F and G), similar to the effects induced
by Hep-EVs.
Second, we transfected LX2 cells with a selected miR-
128-3p antagonist (antagomiR-128-3p) or with negativeFigure 8. Up-regulation of hepatic miR-128-3p in two expe
disease (NAFLD)/nonalcoholic steatohepatitis (NASH). (A) H
trained pathologist for steatosis, inflammation, and ballooning, d
chow, high-fat, choline supplemented L-amino acid (CSAA), o
microphotographs of H&E staining of liver specimens harvested
for 20 weeks, or normal chow. (C) Expression level of miR-128-3
weeks, CSAA or CDAA diet for 20 weeks or normal chow. Me
represent mean ± standard deviation from three independent ex
test with post hoc Mann-Whitney test and Bonferroni correctiocontrol (anticontrol) (Figure 5A). By inhibiting miR-128-3p
in LX2 cells exposed to Hep-EVs (Supplementary
Figure 3C), we rescued both mRNA and protein levels of
PPAR-g which resembled those of untreated cells or cells
treated with EV-free supernatant (Figure 5B and C). The
expression of PPAR-g remained unchanged in LX2 treated
with anticontrol. Inhibition of miR-128-3p also resulted in a
significant abrogation of the profibrogenic markers a-SMA
and collagen-1a1 (Figure 5D) as well as a marked decrease
in HSC mitogenic activity (Figure 5F) and oriented migration
(Figure 5F and G) compared with anticontrol.
To further confirm the role of microRNAs shuttled by
Hep-EVs in HSC activation, we used an alternative loss-of-
function approach by double-silencing Dicer1 and Drosha
(Dcr/Dro-siRNA) in HepG2 followed by exposure to palmitic
acid to generate Hep-EVs with reduced miRNA content
compared with EVs released by HepG2 transfected with
scramble RNA (scRNA) (Figure 6A). The double-silencingrimental models of diet-induced nonalcoholic fatty liver
&E liver specimens were analyzed in a blinded manner by a
etermining the NAFLD activity score analysis score in mice fed
r choline-deficient L-amino acid (CDAA). (B) Representative
from mice fed a high-fat diet for 12 weeks, CSAA or CDAA diet
p in liver samples harvested from mice fed a high fat diet for 12
an values were normalized to U6 small-nuclear RNA. Values
periments. *P < .05, **P < .005, ***P < .0005, Kruskal-Wallis
n.
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mRNA level of Dicer and 60% of Drosha compared with
control and scRNA cells (Figure 6B). Western blot analysis
confirmed that Dicer protein synthesis was blocked by the
siRNA approach (Figure 6C). Knocking-down Dicer/Drosha
in fat-laden HepG2 reduced the level of miR-128-3p of 50%
in EVs compared with EVs released by fat-laden HepG2
transfected with scRNA (Figure 6D).
We further tested whether reducing EV-miRNAs,
including miR-128-3p, could reduce HSC activation.
Indeed, the exposure of LX2 cells to miRNA-reduced EVs
resulted in a significant decrease of HSC mitogenic activity
(Figure 6E) and chemotaxis (Figure 6F and G). This effect
was not observed after the exposure of HSCs to EVs isolated
from HepG2 transfected with scramble RNA (scRNA)
(Figure 6E–G).
To further confirm the role of miR-128-3p in HSC acti-
vation, we transfected palmitic acid-treated HepG2 with
antagomiR-128-3p or with anticontrol (Figure 7A). This
approach resulted in a 90% reduction of miR-128-3p in
both fat-laden HepG2 as well as Hep-derived EVs (Figure 7B
and C). The exposure of miR-128-3p-depleted EVs to LX2
cells resulted in a down-regulation of profibrogenic markers
a-SMA, collagen-1a1, and TIMP-2 and up-regulation of the
HSC quiescent marker, PPAR-g compared with EVs isolatedFigure 9. Hepatocyte-derived extracellular vesicles (EVs) ar
switch from quiescent to activated hepatic stellate cells (H
hepatocytes leading to lipid-induced toxicity (lipotoxicity) and
carry a variety of different bioactive molecules, particularly mic
fat-laden hepatocytes. EVs shuttle miR-128-3p into HSCs, whi
receptor-g (PPAR-g) and consequent phenotypical switch from
128-3p rescues PPAR-g expression and results in HSC inactivfrom fat-laden HepG2 transfected with anticontrol
(Figure 7D). Furthermore, miR-128-3p-depleted Hep-EVs
showed reduced HSC proliferation (Figure 7E) and oriented-
migration compared with control EVs (Figure 7F and G).
To test whether miR-128-3p was differentially expressed
in the liver during lipotoxicity, we measured the level of this
miRNA in liver samples isolated from mice fed high-fat diet
for 12 weeks and mice fed CDAA diet for 20 weeks, which
developed mild and severe NASH, respectively (Figure 8A
and B). Mice fed high-fat or CDAA diets showed significant
up-regulation of miR-128-3p in the liver compared with
mice that received the respective control diets (Figure 8C).
These findings demonstrate that EV-miR-128-3p contrib-
utes to HSC activation, which may be inhibited or reduced
by blocking miR-128-3p.Discussion
The principal findings of this study relate to the mech-
anisms linking overloading of hepatocytes with lipids and
the activation of HSCs the key fibrogenic cells in the liver.
Our data demonstrate that EVs released by hepatocytes
exposed to lipotoxic FFAs are efficiently internalized in HSCs
in a process that depends at least in part on the expression
of VNN1 on the surface of EVs. EVs internalized into HSCse released during lipotoxicity and induce a phenotypical
SC). During liver steatosis, free fatty acids accumulate in the
cell death. Dying hepatocytes produce and release EVs that
roRNAs such as miR-128-3p, which is highly up-regulated in
ch leads to an inhibition of peroxisome proliferator-activated
quiescent to activated HSCs. A selective inhibition of miR-
ation.
November 2015 Extracellular Vesicles and Liver Fibrosis 661not only induce a phenotypic switch from quiescent to
activated HSCs, but also shuttle miRNAs in to the target
cells—that is, miR-128-3p, a specific PPAR-g-targeting
miRNA. Gain- and loss-of-function experiments identified
miR-128-3p as a key mediator of HSC activation induced by
fat-laden hepatocyte-derived EVs.
NAFLD has grown to become the most common chronic
liver disease in both adults and children.40,41 The early stages
of the disease are characterized by the overaccumulation of
fat mainly in the form of triglycerides in the liver resulting in
hepatic steatosis.42 Although this condition appears to be
benign, some patients develop features of hepatocellular
damage and inflammation in a condition termed steatohe-
patitis.8,43 Like other chronic liver disorders, this processmay
trigger an abnormal wound-healing response with develop-
ment of liver fibrosis; this single most important feature of
disease severity in patients with NAFLD44 can lead to
cirrhosis and the need for liver transplantation.45 Recent
research has provided significant information regarding the
molecular and cellular basis for the development of hepatic
fibrosis in NAFLD. In particular, studies have focused on the
crosstalk between inflammatory cells, mainly the resident
liver macrophages, or Kupffer cells, and HSCs, the key cell
responsible for liver scar formation.13,46
The links between damaged parenchymal cells in the
liver, modulation of HSC phenotype, and the development of
liver fibrosis in NAFLD remain incompletely understood.
Previous studies have suggested that hepatocyte death may
be an important signal for the activation of HSCs. Indeed,
engulfment of apoptotic bodies by HSCs stimulates the
fibrogenic activity of these cells and may be one mechanism
by which hepatocyte apoptosis promotes fibrosis.47 Previ-
ous data have also demonstrated that DNA from apoptotic
hepatocytes acts as an important mediator of HSC activation
and differentiation by providing a stop signal when they
have reached an area of apoptotic hepatocytes and inducing
a stationary phenotype-associated up-regulation of collagen
production.48
Lipotoxicity, a process by which an accumulation of
certain toxic lipids, such as saturated FFAs, in hepatocytes
triggers various molecular pathways of cell stress and even-
tually results in cell death, has evolved as a key event during
NAFLD progression. We have recently demonstrated that
during lipotoxicity hepatocytes release EVs, which are
enriched in Vanin-1 (VNN1) on the external leaflet, and are
internalized into endothelial cells where they induce proan-
giogenic effects.16 Through various approaches we identified
VNN1 as an important mediator of the process of internali-
zation. EVs are a heterogeneous population of small
membrane-bound structures released mainly by stressed or
dying cells via exocytosis from the cytosol or ectocytosis from
the plasmamembrane of the parenteral cells.49,50 EVs carry a
variety of different bioactive molecules from the parenteral
cells, including proteins, mRNA, miRNAs, and lipids.51–53 The
wide spectrumof biological activities promoted byEVsmakes
them efficient cell-to-cell communicators.
Circulating levels of EVs are increased in animal models
of NASH and in patients with cirrhosis.17,54 In the former,
the levels of circulating EVs strongly correlated with theseverity of liver fibrosis. In our present study, we observed
that EVs are released in large amounts by hepatocytes
exposed to the lipotoxic fatty acid palmitic acid and are
efficiently internalized into HSCs. Similar to what we pre-
viously observed in endothelial cells, the internalization of
Hep-EVs into HSCs required the presence of VNN1 on their
surface. More importantly, we found that the internalization
of vesicles induced a significant phenotypic switch in HSCs
from quiescent to activated.
A large body of evidence supports a central role of PPAR-
g, a member of the nuclear hormone-receptor superfamily,
as a key modulator of HSC quiescence.18,55 Notably, it has
been shown that PPAR-g progressively decreases during
HSC activation and that it is completely depleted in fully
activated HSCs.25,27 The findings that the internalization of
EVs into HSCs resulted in the transfer of their RNA content
into the HSCs, including various miRNAs that are specific
modulators of PPAR-g expression, led us to investigate their
potential role in the activation of HSCs. We focused our
studies on miR-128-3p, which inhibits PPAR-g expression,
because it was recently identified as being differentially
expressed in the livers of patients with NASH.56 Our findings
show that this miRNA was enriched in EVs derived from fat-
laden hepatocytes and that it was dramatically up-regulated
in liver samples isolated from two murine diet-induced
NAFLD/NASH models. Additionally, miR-128-3p was selec-
tively transferred to HSCs by Hep-EVs. By using both gain-
and loss-of-function approaches, we identified miR-128-3p
as a key mediator of HSC activation induced by EVs in a
process dependent, at least in part, on the modulation of
PPAR-g expression.
In summary, our study uncovers a novel pathway linking
lipotoxicity in liver parenchymal cells to activation of the
main fibrogenic cells in the liver, identifying a potential key
mechanism of liver fibrosis in NASH. The results support a
model in which overloading of hepatocytes with toxic lipids
results in the release of EVs that can be efficiently inter-
nalized by HSCs and induce a phenotypic switch to profi-
brogenic HSCs. This process involves the delivery of miR-
128-3p and suppression of PPAR-g expression (Figure 9).
These findings provide further insight into the pathogenesis
of liver fibrosis in NASH and identify potential molecular
targets for antifibrotic therapeutic interventions.References
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Supplementary
Figure 1. A control neu-
tralizing antibody against
GAPDH does not influ-
ence extracellular vesicle
(EV) internalization or EV-
induced hepatic stellate
cell (HSC) activation. (A)
Representative micropho-
tographs of internalization
of hepatocyte-derived,
PKH26-positive extracel-
lular vesicles (EV, red) into
LX2 and primary mouse
HSCs (F-actin fibers, green
and nuclei, DAPI) after
6 hours of incubation
with EVs incubated with
GAPDH neutralizing anti-
body (GAPDH nAb). (B)
Quantitative PCR analysis
of PPAR-g in human
immortalized HSCs (LX2)
treated with HepG2-
derived EVs (Hep-MP) and
EVs incubatedwith GAPDH
nAb for 16 hours. (C)
Quantitative PCR analyses
for profibrogenic genes
a-SMA, Collagen type 1
and TIMP-2 in LX2 treated
with Hep-EVs and EVs
incubated with glyceralde-
hyde-3-phosphate dehy-
drogenase neutralizing
antibody (GAPDH nAb) for
16 hours. b2-Microglobulin
was used as the control.
Values represent mean ±
standard deviation from
three independent experi-
ments. *P< .05, **P< .005,
***P< .0005, Kruskal-Wallis
test with post hoc Mann-
Whitney test and Bonfer-
roni correction.
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Supplementary Figure 2. Extracellular vesicles (EVs) isolated from primary mouse hepatocytes and incubated with
quiescent mouse primary hepatic stellate cells (HSCs). (A) Representative microphotographs of primary mouse hepato-
cytes exposed to 0.25 mM of palmitic acid for 24 hours. (B) Flow cytometry analysis of the amount of calcein þ EVs isolated
from palmitic acid-treated or vehicle-treated primary mouse hepatocytes. (C) Representative microphotographs of primary
mouse HSCs cultured in vitro from day-1 (quiescent HSCs) to day-7 (activated HSC). Values represent mean ± standard
deviation from three independent experiments. *P < .05, **P < .005, ***P < .0005, Kruskal-Wallis test with post–hoc Mann-
Whitney test and Bonferroni correction.
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Supplementary Figure 3. PPAR-g mRNA expression time-course and miR-128-3p level in hepatic stellate cells (HSCs)
transfected with miR-128-3p mimic or antagomiR-128-3p. (A) Quantitative polymerase chain reaction (qPCR) analysis of
peroxisome proliferator-activated receptor-g (PPAR-g) time-course in LX2 exposed to HepG2-derived extracellular vesicles
(EVs) or controls for 3, 6, 16, or 24 hours. A Vanin-1 neutralizing antibody (VNN1 nAb) was used to block EV internalization. (B)
MiR-128-3p level in LX2 transfected with miR-128-3p MIMIC or exposed to EVs and controls for 16 hours. (C) MiR-128-3p
level in LX2 transfected with AntagomiR-128-3p or exposed to EV and controls for 16 hours. Values represent mean ±
standard deviation from three independent experiments. *P < .05, **P < .005, ***P < .0005, Kruskal-Wallis test with post hoc
Mann-Whitney test and Bonferroni correction.
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Supplementary Table 1.List of primers used for quantitative
polymerase chain reaction
Gene Primers
hTIMP-2
Forward 5-GGGGCCGTGTAGATAAACTCTAT-3
Reverse 5-AAGCGGTCAGTGAGAAGGAAG-3
hCOL1A1
Forward 5-GAGGGCCAAGACGAAGACATC-3
Reverse 5-CAGATCACGTCATCGCACAAC-3
ha-SMA
Forward 5-CTATGAGGGCTATGCCTTGCC-3
Reverse 5-GCTCAGCAGTAGTAACGAAGGA-3
h18S
Forward 5-CAGCCACCCGAGATTGAGCA-3
Reverse 5-TAGTAGCGACGGGCGGTGTG-3
hPPAR-g
Forward 5-TTCGCAATCCATCGGCGAG-3
Reverse 5-CCACAGGATAAGTCACCGAGG-3
mPPAR-g
Forward 5-CGAGGGCGATCTTGACAGGA-3
Reverse 5-GGCCACCTCTTTGCTCTGCT-3
hGAPDH
Forward 5-ACAACTTTGGTATCGTGGAAGG-3
Reverse 5-GCCATCACGCCACAGTTTC-3
m18S
Forward 5-ACGGAAGGGCACCACCAGGA-3
Reverse 5-CACCACCACCCACGGAATCG-3
hDICER
Forward 5-GAGCTGTCCTATCAGATCAGGG-3
Reverse 5-ACTTGTTGAGCAACCTGGTTT-3
hDROSHA
Forward 5-ATCCTTTAGGCCCCAAAATCTG-3
Reverse 5-GGGTACAAAGTCTGGTCGTGG-3
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